We completed a ~$345 million public financing following the publication of positive long-term data from the ORIGIN Phase 2b trial in #IgANephropathy and the expansion of our development program into multiple autoimmune kidney diseases! Learn more here: https://lnkd.in/eKsBkT2C
Vera Therapeutics, Inc.
Biotechnology Research
Brisbane, California 10,048 followers
We are a clinical-stage biotechnology company developing treatments that transform patients’ lives.
About us
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for serious immunological diseases to improve patients’ lives.
- Website
-
http://www.veratx.com
External link for Vera Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Brisbane, California
- Type
- Public Company
Locations
-
Primary
Get directions
2000 Sierra Point Pkwy
1200
Brisbane, California 94005, US
Employees at Vera Therapeutics, Inc.
Updates
-
We're attending the 4th Annual Rare & Genetic Kidney Disease Drug Development Summit, where our SVP of Medical Affairs, Kerry Cooper, MD will review recent data in the #IgANephropathy treatment landscape. Register here: https://lnkd.in/eg_KivC2
-
-
Join us for a fireside chat at the Guggenheim Securities Healthcare Innovation Conference on Wednesday Nov 13 at 9:30 am ET. Learn more and register for the webcast: https://lnkd.in/e6UKUK5a $VERA
-
-
#ICYMI, this Fierce Biotech article covers the positive 96-week data from the ORIGIN Phase 2b trial in #IgANephropathy presented at #KidneyWk. Read it here: https://lnkd.in/eVZxWxdz
-
-
Today we provided a business update and reported Q3 financial results. Read the full release here: https://lnkd.in/eKsBkT2C $VERA
-
-
Thank you Shikha Wadhwani and Brendon L Neuen for your interest in atacicept, our investigational therapy for #IgANephropathy.
Live from #KidneyWk! In this special edition of #KidneyCompass, hosts Shikha Wadhwani, MD, MS, of The University of Texas Medical Branch, and Brendon L Neuen, MBBS, PhD, of The George Institute for Global Health and Royal North Shore Hospital, are joined by Jonathan Barratt, PhD, of the University of Leicester, for a deep dive into atacicept, 96-week data from the phase 2b ORIGIN trial, and the evolving treatment of IgA nephropathy. Learn more using the link below: https://lnkd.in/e9brQ62n
-
Yesterday we presented long-term results showing eGFR stabilization through 96 weeks in the ORIGIN Phase 2b trial of atacicept, an investigational therapy for #IgANephropathy. Join our virtual investor event on Monday Oct 28 at 8am ET and read the press release for more information: https://lnkd.in/euudSjzA
-
Team Vera is at American Society of Nephrology #KidneyWk! Visit us at booth 2321 and don’t miss our late breaking oral presentation of long term data from the Phase 2b trial of atacicept in #IgANephropathy on Saturday: https://lnkd.in/ePxtHhts
-
-
Continuing our series on Vera leaders, we're excited to welcome Reginald Gay, MD as VP of Pharmacovigilance and Donald Mallet, PharmD, MBA as VP of Field Medical Affairs. Regi and Don bring rich experience in medical affairs and drug safety across multiple therapeutic areas and companies large and small. Learn more about our talented leadership team: https://lnkd.in/eCD_xbpt
-
We're kicking off a series of features on the talented and experienced leaders of Vera, starting with the newest addition to our team: Matt Skelton, EVP of Commercial. Matt's industry expertise will be invaluable as our organization prepares for potential commercialization. Learn more about our leadership team: https://lnkd.in/eCD_xbpt